We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

President of Lilly Diabetes and Obesity and President of Lilly USA; Eli Lilly and Co Anne White; Executive Vice President, President - Lilly Neuroscience; Eli Lilly and Co Good morning.

Our assumptions for overall biopharma GLP-1 sales in 2031 surpass $200 billion across diabetes, obesity, and overweight patients with Lilly capturing $75 billion of the market. We think more than ...